Table I.
Baseline Patient Characteristics by Treatment
| Parameter | Nebivolol Dose | |||||||
|---|---|---|---|---|---|---|---|---|
| Placebo (n=81) | 1.25 mg (n=83) | 2.5 mg (n=82) | 5 mg (n=166) | 10 mg (n=166) | 20 mg (n=166) | 40 mg (n=166) | Total (N=909) | |
| Age, y, mean (SD) | 56.0 (11.6) | 55.5 (11.5) | 53.4 (12.3) | 54.9 (11.8) | 55.2 (12.5) | 54.1 (11.6) | 54.3 (11.6) | 54.7 (11.8) |
| Younger than 65 y, No. (%) | 64 (79.0) | 65 (78.3) | 68 (82.9) | 132 (80.0) | 125 (75.3) | 134 (80.7) | 128 (77.1) | 716 (78.8) |
| Aged 65 y or older, No. (%) | 17 (21.0) | 18 (21.7) | 14 (17.1) | 33 (20.0) | 41 (24.7) | 32 (19.3) | 38 (22.9) | 193 (21.2) |
| Sex, No. (%) | ||||||||
| Male | 46 (56.8) | 46 (55.4) | 53 (64.6) | 96 (58.2) | 93 (56.0) | 92 (55.4) | 92 (55.4) | 518 (57.0) |
| Female | 35 (43.2) | 37 (44.6) | 29 (35.4) | 69 (41.8) | 73 (44.0) | 74 (44.6) | 74 (44.6) | 391 (43.0) |
| Race, No. (%) | ||||||||
| Black | 11 (13.6) | 12 (14.5) | 13 (15.9) | 23 (13.9) | 23 (13.9) | 25 (15.1) | 25 (15.1) | 132 (14.5) |
| Nonblack | 70 (86.4) | 71 (85.5) | 69 (84.1) | 142 (86.1) | 143 (86.1) | 141 (84.9) | 141 (84.9) | 777 (85.5) |
| Diabetes mellitus, No. (%) | 7 (8.6) | 9 (10.8) | 10 (12.2) | 11 (6.7) | 17 (10.2) | 14 (8.4) | 20 (12.0) | 88 (9.7) |
| Body mass index, kg/m2, mean (SD) | 29.1 (4.2) | 29.3 (4.2) | 29.4 (3.9) | 29.2 (3.7) | 29.0 (4.1) | 28.7 (4.1) | 29.4 (3.9) | 29.1 (4.0) |
| <30, No. (%) | 44 (54.3) | 43 (51.8) | 45 (54.9) | 91 (55.2) | 102 (61.4) | 101 (60.8) | 84 (50.6) | 501 (56.1) |
| ≥30, No. (%) | 37 (45.7) | 40 (48.2) | 37 (45.1) | 74 (44.8) | 64 (38.6) | 65 (39.2) | 82 (49.4) | 399 (43.9) |